GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Shiller PE Ratio

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tonix Pharmaceuticals Holding Shiller PE Ratio Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Shiller PE Ratio Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tonix Pharmaceuticals Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tonix Pharmaceuticals Holding's Shiller PE Ratio

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Shiller PE Ratio falls into.



Tonix Pharmaceuticals Holding Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Tonix Pharmaceuticals Holding's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Tonix Pharmaceuticals Holding's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.466/129.4194*129.4194
=-0.466

Current CPI (Dec. 2023) = 129.4194.

Tonix Pharmaceuticals Holding Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -105,388.000 99.695 -136,810.473
201406 -123,347.000 100.560 -158,746.759
201409 -139,981.000 100.428 -180,390.858
201412 -166,463.000 99.070 -217,458.432
201503 -121,012.000 99.621 -157,208.668
201506 -147,038.000 100.684 -189,003.105
201509 -140,957.000 100.392 -181,714.292
201512 -142,128.000 99.792 -184,323.861
201603 -148,681.000 100.470 -191,521.143
201606 -78,448.000 101.688 -99,841.506
201609 -51,904.100 101.861 -65,946.707
201612 -38,369.200 101.863 -48,749.138
201703 -24,346.200 102.862 -30,631.958
201706 -12,780.700 103.349 -16,004.692
201709 -15,266.500 104.136 -18,973.159
201712 -14,048.600 104.011 -17,480.455
201803 -17,337.500 105.290 -21,310.851
201806 -13,834.100 106.317 -16,840.245
201809 -10,456.100 106.507 -12,705.512
201812 -6,679.380 105.998 -8,155.269
201903 -2,552.000 107.251 -3,079.504
201906 -1,884.000 108.070 -2,256.198
201909 -1,138.000 108.329 -1,359.550
201912 -572.000 108.420 -682.788
202003 -74.000 108.902 -87.942
202006 -46.000 108.767 -54.734
202009 -18.000 109.815 -21.213
202012 -20.000 109.897 -23.553
202103 -14.000 111.754 -16.213
202106 -14.063 114.631 -15.877
202109 -10.000 115.734 -11.182
202112 -14.000 117.630 -15.403
202203 -10.063 121.301 -10.736
202206 -7.640 125.017 -7.909
202209 -4.240 125.227 -4.382
202212 -3.500 125.222 -3.617
202303 -3.250 127.348 -3.303
202306 -2.680 128.729 -2.694
202309 -1.830 129.860 -1.824
202312 -0.466 129.419 -0.466

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tonix Pharmaceuticals Holding  (NAS:TNXP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Tonix Pharmaceuticals Holding Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Traded in Other Exchanges
N/A
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.
Executives
Richard Newcomb Stillwell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman director, 10 percent owner, officer: Chief Executive Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan officer: Chief Medical Officer C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange director
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris officer: Chief Administrative Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes director 74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Headlines

From GuruFocus